Stockscreener 앱 받기
29.41
3.78%
1.07
전일 마감가:
$28.34
열려 있는:
$28.73
하루 거래량:
123.47K
Relative Volume:
0.24
시가총액:
$1.51B
수익:
$413.05M
순이익/손실:
$-27.67M
주가수익비율:
-52.42
EPS:
-0.561
순현금흐름:
$-30.75M
1주 성능:
+1.10%
1개월 성능:
-7.44%
6개월 성능:
-7.05%
1년 성능:
-14.48%
1일 변동 폭
$28.73
$29.90
1주일 범위
$27.50
$29.73
52주 변동 폭
$27.50
$40.71
이뮤노코어 홀딩스 Stock (IMCR) Company Profile
명칭
Immunocore Holdings Plc Adr
전화
01235 5430281
주소
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
29.41 | 1.51B | 413.05M | -27.67M | -30.75M | -0.561 |
VRTX
Vertex Pharmaceuticals Inc
|
509.10 | 129.04B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.23 | 95.11B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.96 | 82.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.89 | 53.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.80 | 42.06B | 5.76B | 514.49M | 1.10B | 4.4813 |
이뮤노코어 홀딩스 Stock (IMCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-21 | 재개 | JP Morgan | Overweight |
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-01-07 | 업그레이드 | UBS | Sell → Buy |
| 2025-10-31 | 개시 | Wells Fargo | Overweight |
| 2025-09-18 | 재개 | Guggenheim | Neutral |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2025-05-27 | 개시 | Deutsche Bank | Buy |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-10-24 | 개시 | UBS | Sell |
| 2024-10-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 개시 | Robert W. Baird | Outperform |
| 2023-09-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 개시 | Needham | Buy |
| 2023-08-16 | 개시 | CapitalOne | Overweight |
| 2023-07-17 | 개시 | Canaccord Genuity | Hold |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-30 | 개시 | Guggenheim | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2022-12-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-30 | 개시 | Barclays | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-09-08 | 개시 | Ladenburg Thalmann | Buy |
| 2022-08-08 | 개시 | Cowen | Outperform |
| 2022-08-02 | 개시 | BTIG Research | Buy |
| 2022-02-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-20 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | Goldman | Neutral |
| 2021-03-02 | 개시 | JP Morgan | Overweight |
| 2021-03-02 | 개시 | Jefferies | Buy |
모두보기
이뮤노코어 홀딩스 주식(IMCR)의 최신 뉴스
Price to earnings ratio of Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh – HAN:6YG - TradingView
Editas Medicine, Inc. (EDIT) Stock Price & News - Syfe
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh - TradingView
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – HAN:6YG - TradingView
Form 8K Immunocore Holdings plc For: 14 September By Investing.com - Investing.com South Africa
Immunocore Achieves Full Enrollment in Phase 3 TEBE-AM Melanoma Study - Kalkine Media
Immunocore at cantor global healthcare conference: growth, trials and cash - Investing.com
Prime Medicine, Inc. (PRME) Stock Price & News - Syfe
Immunocore (IMCR) Technicals: Closes 1.65% Higher at $36.88 for the Current Session; Range View - dars.gov.et
Immunocore (IMCR) Technicals: Closes 1.65% Higher at $36.88 for the Current Session; Range View - dars.gov.et
ProKidney Corp. Class A (PROK) Stock Price & News - Syfe
Immunocore (IMCR) Earnings Review: The Available Earnings Metric Delivers a Miss; Share-Price Check: Shares Finish 2.77% Up at the CloseEarnings Surprise Stocks - careplusvn.com
Immunocore (IMCR) Earnings Review: The Available Earnings Metric Delivers a Miss; Share-Price Check: Shares Finish 2.77% Up at the CloseEarnings Surprise Stocks - dars.gov.et
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - MarketBeat
Q3 Earnings Forecast for Immunocore Issued By HC Wainwright - MarketBeat
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum - Yahoo Finance
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation? - Yahoo Finance
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss - TradingView
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - TradingView
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - Zacks Investment Research
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance Singapore
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Zacks Investment Research
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
Immunocore Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Immunocore posts Q2 2026 revenue beat as EPS misses - Investing.com
Immunocore Holdings earnings missed by $0.03, revenue topped estimates - Investing.com
Immunocore set to report earnings ahead of pivotal trial data - Investing.com
Immunocore Holdings PLC Sponsored ADR $IMCR Position Boosted by Janus Henderson Group PLC - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Stempoint Capital LP Purchases New Shares in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Eversept Partners LP Takes Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak - Yahoo! Finance Canada
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak - Zacks Investment Research
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth? - TradingView
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead - TradingView
IMCR|Immunocore Holdings PLC|Price:32.000|Chg%:-0.300 - TradingKey
Principal Financial Group Inc. Sells 139,306 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors - TradingView
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib - TradingView
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push - TradingView
Is it a good idea to invest in Immunocore stock right now? - MSN
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - TradingView
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed - TradingView
IMCR News | IMMUNOCORE HOLDINGS PLC-ADR (NASDAQ:IMCR) - ChartMill
이뮤노코어 홀딩스 (IMCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤노코어 홀딩스 주식 (IMCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| David Berman | Affiliate |
May 21 '26 |
Proposed Sale |
29.15 |
65,000 |
1,894,638 |
0 |
| David Berman | Affiliate |
Apr 08 '26 |
Proposed Sale |
31.85 |
25,000 |
796,250 |
0 |
| David Berman | affiliate |
Mar 11 '26 |
Proposed Sale |
32.57 |
11,832 |
385,330 |
0 |
| Bahija Jallal | affiliate |
Feb 18 '26 |
Proposed Sale |
32.35 |
11,474 |
371,152 |
0 |
| Tina St Leger | affiliate |
Feb 18 '26 |
Proposed Sale |
32.35 |
1,000 |
32,347 |
0 |
| David Berman | affiliate |
Feb 18 '26 |
Proposed Sale |
32.35 |
5,965 |
192,951 |
0 |
| Berman David M | HEAD OF R&D |
Feb 18 '26 |
Sale |
32.35 |
5,965 |
192,968 |
5,859 |
| St Leger Tina Amber | CHIEF HR OFFICER |
Feb 18 '26 |
Sale |
32.35 |
1,000 |
32,350 |
1,119 |
| GOLL JOHN | SVP, FINANCE & CAO |
Feb 18 '26 |
Sale |
32.35 |
698 |
22,580 |
653 |
| Jallal Bahija | CHIEF EXECUTIVE OFFICER |
Feb 18 '26 |
Sale |
32.35 |
11,474 |
371,184 |
12,343 |
8.58%
0.23%
자본화:
|
볼륨(24시간):